(WSJ) – Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug development Drug companies have been talking about the potential for AI to supercharge drug development for years, but it hasn’t materialized in a big way yet. “There was this promise you’d see dramatic improvement” in the rate of success of drug clinical trials as a result of AI, said RBC Capital Markets analyst Trung Huyn…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.